Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS

Localized Cancer Therapy

Descrizione del progetto

Un trattamento oncologico innovativo basato su nanovettori

I metodi convenzionali di trattamento oncologico impiegati al giorno d’oggi sono associati a ostacoli clinici, come la non specificità, gli effetti collaterali e la tolleranza ai farmaci. Recentemente sono state sviluppate terapie localizzate che sfruttano farmaci su scala nanometrica e che rappresentano un’opzione non invasiva, controllabile e con effetti collaterali minimi. Questo trattamento permette di trasportare i nanovettori nell’esatta posizione del tumore bersaglio, rilasciando i farmaci chemioterapici dopo l’attivazione. I timori sulla sicurezza di questa tecnologia sono associati alla mancanza di biodegradazione, alla potenziale tossicità, alla scarsa biodisponibilità e alle complicanze portate dall’attivazione del farmaco. Il progetto LCT, finanziato dal programma di azioni Marie Skłodowska-Curie, si propone di introdurre nanovettori innovativi atossici, biocompatibili e biodegradabili da applicare in combinazione con trattamenti consolidati come la radioterapia, precisa ed efficace.

Obiettivo

Currently, cancer is the second cause of morbidity and death in Europe, with 1.9m deaths and 3.7m cases annually. Cancer-related deaths are projected to exceed 13m by 2030, with abdominal organs hosting most cancer incidents. Although popular, conventional modalities are nonetheless associated with major clinical challenges such as non-specificity, side effects, and drug tolerance, which impede further developments. In recent years, non-invasive, controllable, minimal side effects, and localized nano-scale drug-based therapies have been developed. This treatment deploys nanocarriers (NCs) to the location of the targeted cancer tumors, and upon activation, they release chemotherapeutic drugs. However, there are concerns over the safety of this strategy due to lack of biodegradation, potential toxicity, poor bioavailability, and limitations associated with the drug activation protocols.

The main goal of the LCT project is to overcome these challenges in an original and innovative manner by developing nanocarriers that are nontoxic, biocompatible, biodegradable, and can be combined with a well-known treatment modality (e.g. a precise and effective radiation treatment). The proposed work will be approached from theoretical, numerical, and experimental perspectives based on the applicant's and host laboratory's expertise. The training program is exhaustive and will allow the applicant to grow as an independent researcher. The proposed research will foster further development in this direction, a step that is fundamental in healthcare and for the benefit of society.

The applicant is a Libyan scholar with expertise in the areas of applied mechanics, industrial & medical radiation, materials science, nano-chemistry, and structural engineering. He has been trained in prestigious industrial and academic institutions in Libya, Canada, and Hong Kong. He is applying for a two-year MSCA fellowship to conduct the LCT at NUI Galway. A 4 months secondment at UCD is planned.

Campo scientifico (EuroSciVoc)

Parole chiave

Programma(i)

Argomento(i)

Meccanismo di finanziamento

HORIZON-TMA-MSCA-PF-EF - HORIZON TMA MSCA Postdoctoral Fellowships - European Fellowships

Vedi tutti i progetti finanziati nell’ambito di questo schema di finanziamento

Invito a presentare proposte

(si apre in una nuova finestra) HORIZON-MSCA-2021-PF-01

Vedi tutti i progetti finanziati nell’ambito del bando

Coordinatore

UNIVERSITY OF GALWAY
Contributo netto dell'UE
€ 199 694,40
Indirizzo
UNIVERSITY ROAD
H91 Galway
Irlanda
Regione
Ireland Northern and Western West
Tipo di attività
Higher or Secondary Education Establishments
Collegamenti
Costo totale
Nessun dato

Partner (1)